Detalles de la búsqueda
1.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol
; 2024 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278303
2.
Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit.
Sci Rep
; 13(1): 2007, 2023 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36737654
3.
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.
Lung Cancer
; 178: 229-236, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898331
4.
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer.
Lung Cancer
; 172: 136-141, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36087486
5.
Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Thorac Cancer
; 13(12): 1763-1771, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35538909
6.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Oncoimmunology
; 10(1): 1865653, 2021 01 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33552685
7.
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
J Immunother Cancer
; 9(2)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33597218
8.
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC.
J Oncol
; 2020: 1980891, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32963526
Resultados
1 -
8
de 8
1
Próxima >
>>